An Open Letter to Shareholders from TeraWulf Chairman and CEO Paul Prager
February 2023
Dear Shareholders,
It has been four weeks since I shared my reflections on TeraWulf's achievements in 2022 and stated goals
Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand the therapeutic potential of proteins, today announced that it has entered into a research collaboration with Merck (known as MSD outside the United States and Canada), using Absci's AI-powered In